Emily Field
Stock Analyst at Barclays
(0.96)
# 3,897
Out of 5,174 analysts
15
Total ratings
25%
Success rate
-3.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underweight | $25 | $26.77 | -6.61% | 1 | Feb 20, 2026 | |
| MRK Merck & Co. | Initiates: Overweight | $140 | $115.68 | +21.02% | 1 | Feb 20, 2026 | |
| GILD Gilead Sciences | Initiates: Equal-Weight | $155 | $137.34 | +12.86% | 1 | Feb 20, 2026 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $1,350 | $910.55 | +48.26% | 1 | Feb 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $75 | $57.00 | +31.58% | 1 | Feb 20, 2026 | |
| BIIB Biogen | Initiates: Equal-Weight | $185 | $183.64 | +0.74% | 1 | Feb 20, 2026 | |
| AMGN Amgen | Initiates: Equal-Weight | $350 | $349.77 | +0.07% | 1 | Feb 20, 2026 | |
| ABBV AbbVie | Initiates: Overweight | $275 | $204.93 | +34.19% | 1 | Feb 20, 2026 | |
| NVO Novo Nordisk | Downgrades: Equal-Weight | n/a | $36.82 | - | 1 | Jul 30, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | n/a | $31.90 | - | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | n/a | $51.99 | - | 4 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $681.85 | - | 1 | Oct 19, 2021 |
Pfizer
Feb 20, 2026
Initiates: Underweight
Price Target: $25
Current: $26.77
Upside: -6.61%
Merck & Co.
Feb 20, 2026
Initiates: Overweight
Price Target: $140
Current: $115.68
Upside: +21.02%
Gilead Sciences
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $155
Current: $137.34
Upside: +12.86%
Eli Lilly and Company
Feb 20, 2026
Initiates: Overweight
Price Target: $1,350
Current: $910.55
Upside: +48.26%
Bristol-Myers Squibb Company
Feb 20, 2026
Initiates: Overweight
Price Target: $75
Current: $57.00
Upside: +31.58%
Biogen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $185
Current: $183.64
Upside: +0.74%
Amgen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $350
Current: $349.77
Upside: +0.07%
AbbVie
Feb 20, 2026
Initiates: Overweight
Price Target: $275
Current: $204.93
Upside: +34.19%
Novo Nordisk
Jul 30, 2025
Downgrades: Equal-Weight
Price Target: n/a
Current: $36.82
Upside: -
Galapagos NV
Jan 23, 2025
Downgrades: Underweight
Price Target: n/a
Current: $31.90
Upside: -
Nov 5, 2021
Upgrades: Equal-Weight
Price Target: n/a
Current: $51.99
Upside: -
Oct 19, 2021
Upgrades: Overweight
Price Target: n/a
Current: $681.85
Upside: -